- Home
- TVTX
as 10-03-2025 4:00pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.5B | IPO Year: | N/A |
| Target Price: | $35.20 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.91 - $28.69 | Next Earning Date: | 10-30-2025 |
| Revenue: | $333,865,000 | Revenue Growth: | 87.94% |
| Revenue Growth (this year): | 83.87% | Revenue Growth (next year): | 40.99% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Sep 22 '25 | Sell | $25.00 | 10,000 | $250,000.00 | 89,878 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Sep 4 '25 | Sell | $19.71 | 119 | $2,345.49 | 92,083 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Sep 3 '25 | Sell | $18.20 | 454 | $8,262.80 | 92,083 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Aug 27 '25 | Sell | $17.31 | 470 | $8,135.70 | 92,083 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
22 days ago
Hims & Hers Leads 15 Growth Stocks Amid Medical Boom
Business Wire
23 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
23 days ago
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Insider Monkey
23 days ago
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside
Zacks
23 days ago
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Investor's Business Daily
24 days ago
Why Top 4% Stock Travere Therapeutics Skyrocketed To A Three-Year High
Simply Wall St.
24 days ago
Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results
MT Newswires
24 days ago
Sector Update: Health Care Stocks Advance Pre-Bell Wednesday
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.